Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 13 (July 1), 2004: pp. 2610-2616
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.12.040
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiong, H. Q.
Right arrow Articles by Abbruzzese, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiong, H. Q.
Right arrow Articles by Abbruzzese, J. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination With Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial

Henry Q. Xiong, Arthur Rosenberg, Albert LoBuglio, William Schmidt, Robert A. Wolff, John Deutsch, Michael Needle, James L. Abbruzzese

From the Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX; Greenwich Hospital/Bendheim Cancer Center, Greenwich, CT; Comprehensive Cancer Center, Clinical Studies Unit, University of Alabama, Birmingham, AL; University of Colorado Health Sciences Center, Denver, CO; Trident Palmetto Hematology/Oncology Group, Charleston, SC; and ImClone Systems Inc, Somerville, NJ

Address reprint requests to James L. Abbruzzese, MD, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: jabbruzz{at}mdanderson.org

PURPOSE: To determine the response rate, time to disease progression, survival duration and rate, and toxicity with the combination of cetuximab and gemcitabine in patients with epidermal growth factor receptor (EGFR)-expressing advanced pancreatic cancer.

PATIENTS AND METHODS: Patients with measurable locally advanced or metastatic pancreatic cancer who had never received chemotherapy for their advanced disease and had immunohistochemical evidence of EGFR expression were eligible for the multicenter phase II trial. Patients were treated with cetuximab at an initial dose of 400 mg/m2, followed by 250 mg/m2 weekly for 7 weeks. Gemcitabine was administered at 1,000 mg/m2 for 7 weeks, followed by 1 week of rest. In subsequent cycles, cetuximab was administered weekly, and gemcitabine was administered weekly for 3 weeks every 4 weeks.

RESULTS: Sixty-one patients were screened for EGFR expression, 58 patients (95%) had at least 1+ staining, and 41 were enrolled onto the trial. Five patients (12.2%) achieved a partial response, and 26 (63.4%) had stable disease. The median time to disease progression was 3.8 months, and the median overall survival duration was 7.1 months. One-year progression-free survival and overall survival rates were 12% and 31.7%, respectively. The most frequently reported grade 3 or 4 adverse events were neutropenia (39.0%), asthenia (22.0%), abdominal pain (22.0%), and thrombocytopenia (17.1%).

CONCLUSION: Cetuximab in combination with gemcitabine showed promising activity against advanced pancreatic cancer. Further clinical investigation is warranted.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
N. Starling, D. Watkins, D. Cunningham, J. Thomas, J. Webb, G. Brown, K. Thomas, J. Oates, and I. Chau
Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer
J. Clin. Oncol., November 20, 2009; 27(33): 5499 - 5505.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Lorenzen, T. Schuster, R. Porschen, S.-E. Al-Batran, R. Hofheinz, P. Thuss-Patience, M. Moehler, P. Grabowski, D. Arnold, T. Greten, et al.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
Ann. Onc., October 1, 2009; 20(10): 1667 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Poplin, Y. Feng, J. Berlin, M. L. Rothenberg, H. Hochster, E. Mitchell, S. Alberts, P. O'Dwyer, D. Haller, P. Catalano, et al.
Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
J. Clin. Oncol., August 10, 2009; 27(23): 3778 - 3785.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Benkoel, J.-P. Bernard, M.-J. Payan-Defais, L. Crescence, C. Franceschi, M. Delmas, M. Ouaissi, B. Sastre, J. Sahel, A.-M. Benoliel, et al.
Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues
Mol. Cancer Ther., February 1, 2009; 8(2): 282 - 291.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Wilke, R. Glynne-Jones, J. Thaler, A. Adenis, P. Preusser, E. A. Aguilar, M. S. Aapro, R. Esser, A. H. Loos, and S. Siena
Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study
J. Clin. Oncol., November 20, 2008; 26(33): 5335 - 5343.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Lei, M. Abdelrahim, S. D. Cho, X. Liu, and S. Safe
Structure-dependent activation of endoplasmic reticulum stress-mediated apoptosis in pancreatic cancer by 1,1-bis(3'-indoly)-1-(p-substituted phenyl)methanes
Mol. Cancer Ther., October 1, 2008; 7(10): 3363 - 3372.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. A. Danovi, H. H. Wong, and N. R. Lemoine
Targeted therapies for pancreatic cancer
Br. Med. Bull., September 1, 2008; 87(1): 97 - 130.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Kleespies, I. Ischenko, M. E. Eichhorn, H. Seeliger, C. Amendt, O. Mantell, K.-W. Jauch, and C. J. Bruns
Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine
Clin. Cancer Res., September 1, 2008; 14(17): 5426 - 5436.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
P Ghaneh, E Costello, and J P Neoptolemos
Biology and management of pancreatic cancer
Postgrad. Med. J., September 1, 2008; 84(995): 478 - 497.
[Full Text] [PDF]

Home page
 The OncologistHome page
L. Dal Lago, V. D'Hondt, and A. Awada
Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors
Oncologist, August 1, 2008; 13(8): 845 - 858.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Ali, S. Banerjee, A. Ahmad, B. F. El-Rayes, P. A. Philip, and F. H. Sarkar
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer
Mol. Cancer Ther., June 1, 2008; 7(6): 1708 - 1719.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Cao, M. Bloomston, T. Zhang, W. L. Frankel, G. Jia, B. Wang, N. C. Hall, R. M. Koch, H. Cheng, M. V. Knopp, et al.
Synergistic Antipancreatic Tumor Effect by Simultaneously Targeting Hypoxic Cancer Cells With HSP90 Inhibitor and Glycolysis Inhibitor
Clin. Cancer Res., March 15, 2008; 14(6): 1831 - 1839.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Ciardiello and G. Tortora
EGFR Antagonists in Cancer Treatment
N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Laheru, E. Lutz, J. Burke, B. Biedrzycki, S. Solt, B. Onners, I. Tartakovsky, J. Nemunaitis, D. Le, E. Sugar, et al.
Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
Clin. Cancer Res., March 1, 2008; 14(5): 1455 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Burris III and C. Rocha-Lima
New Therapeutic Directions for Advanced Pancreatic Cancer: Targeting the Epidermal Growth Factor and Vascular Endothelial Growth Factor Pathways
Oncologist, March 1, 2008; 13(3): 289 - 298.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Zhang, A. Hamza, X. Cao, B. Wang, S. Yu, C.-G. Zhan, and D. Sun
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
Mol. Cancer Ther., January 1, 2008; 7(1): 162 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
J. C. Bendell
Latest Data on the Treatment of Upper Gastrointestinal Cancers
ASCO Educational Book, January 1, 2008; 2008(1): 184 - 190.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. L. Mahtani and J. S. Macdonald
Synergy Between Cetuximab and Chemotherapy in Tumors of the Gastrointestinal Tract
Oncologist, January 1, 2008; 13(1): 39 - 50.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
P. Ghaneh, E. Costello, and J. P Neoptolemos
Biology and management of pancreatic cancer
Gut, August 1, 2007; 56(8): 1134 - 1152.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
R. M. Thomas, K. Toney, C. Fenoglio-Preiser, M. P. Revelo-Penafiel, S. R. Hingorani, D. A. Tuveson, S. E. Waltz, and A. M. Lowy
The RON Receptor Tyrosine Kinase Mediates Oncogenic Phenotypes in Pancreatic Cancer Cells and Is Increasingly Expressed during Pancreatic Cancer Progression
Cancer Res., July 1, 2007; 67(13): 6075 - 6082.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Welch and M. J. Moore
Combination Chemotherapy in Advanced Pancreatic Cancer: Time to Raise the White Flag?
J. Clin. Oncol., June 1, 2007; 25(16): 2159 - 2161.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Larbouret, B. Robert, I. Navarro-Teulon, S. Thezenas, M.-Z. Ladjemi, S. Morisseau, E. Campigna, F. Bibeau, J.-P. Mach, A. Pelegrin, et al.
In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas
Clin. Cancer Res., June 1, 2007; 13(11): 3356 - 3362.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, H. J. Au, P. Murawa, D. Walde, R. A. Wolff, et al.
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., May 20, 2007; 25(15): 1960 - 1966.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Van Cutsem, C. Verslype, and P. A. Grusenmeyer
Lessons Learned in the Management of Advanced Pancreatic Cancer
J. Clin. Oncol., May 20, 2007; 25(15): 1949 - 1952.
[Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. R. Alberts, G. J. Gores, G. P. Kim, L. R. Roberts, M. L. Kendrick, C. B. Rosen, S. T. Chari, and J. A. Martenson
Treatment Options for Hepatobiliary and Pancreatic Cancer
Mayo Clin. Proc., May 1, 2007; 82(5): 628 - 637.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
J. Tabernero
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents
Mol. Cancer Res., March 1, 2007; 5(3): 203 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Taieb, T Lecomte, T Aparicio, A Asnacios, T Mansourbakht, P Artru, D Fallik, J. Spano, B Landi, G Lledo, et al.
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study
Ann. Onc., March 1, 2007; 18(3): 498 - 503.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Nakachi, J. Furuse, H. Ishii, E.-i. Suzuki, and M. Yoshino
Prognostic Factors in Patients with Gemcitabine-Refractory Pancreatic Cancer
Jpn. J. Clin. Oncol., February 1, 2007; 37(2): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. M. Fracasso, H. Burris III, M. A. Arquette, R. Govindan, F. Gao, L. P. Wright, S. A. Goodner, F. A. Greco, S. F. Jones, N. Willcut, et al.
A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Clin. Cancer Res., February 1, 2007; 13(3): 986 - 993.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Shrader, M. S. Pino, G. Brown, P. Black, L. Adam, M. Bar-Eli, C. P.N. Dinney, and D. J. McConkey
Molecular correlates of gefitinib responsiveness in human bladder cancer cells
Mol. Cancer Ther., January 1, 2007; 6(1): 277 - 285.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rosell, M. Taron, N. Reguart, D. Isla, and T. Moran
Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway
Clin. Cancer Res., December 15, 2006; 12(24): 7222 - 7231.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Bianco, E. Giovannetti, F. Ciardiello, V. Mey, S. Nannizzi, G. Tortora, T. Troiani, F. Pasqualetti, G. Eckhardt, M. de Liguoro, et al.
Synergistic Antitumor Activity of ZD6474, An Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, with Gemcitabine and Ionizing Radiation against Pancreatic Cancer
Clin. Cancer Res., December 1, 2006; 12(23): 7099 - 7107.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Van Cutsem
Challenges in the Use of Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 1010 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer.
Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. R. Cardenes, E. G. Chiorean, J. DeWitt, M. Schmidt, and P. Loehrer
Locally advanced pancreatic cancer: current therapeutic approach.
Oncologist, June 1, 2006; 11(6): 612 - 623.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Tanaka, S. C. Pero, K. Taguchi, M. Shimada, M. Mori, D. N. Krag, and S. Arii
Specific Peptide ligand for grb7 signal transduction protein and pancreatic cancer metastasis.
J Natl Cancer Inst, April 5, 2006; 98(7): 491 - 498.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Pino, M. Shrader, C. H. Baker, F. Cognetti, H. Q. Xiong, J. L. Abbruzzese, and D. J. McConkey
Transforming Growth Factor {alpha} Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines.
Cancer Res., April 1, 2006; 66(7): 3802 - 3812.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
D. A Frieze and J. S McCune
Current Status of Cetuximab for the Treatment of Patients with Solid Tumors
Ann. Pharmacother., February 1, 2006; 40(2): 241 - 250.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. S. P. Rocha Lima and A. M. Flores
Gemcitabine Doublets in Advanced Pancreatic Cancer: Should We Move On?
J. Clin. Oncol., January 20, 2006; 24(3): 327 - 329.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Y. Chun, F. Y. Feng, A. M. Scheurer, M. A. Davis, T. S. Lawrence, and M. K. Nyati
Synergistic Effects of Gemcitabine and Gefitinib in the Treatment of Head and Neck Carcinoma
Cancer Res., January 15, 2006; 66(2): 981 - 988.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Yokoi, T. Sasaki, C. D. Bucana, D. Fan, C. H. Baker, Y. Kitadai, T. Kuwai, J. L. Abbruzzese, and I. J. Fidler
Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse Model
Cancer Res., November 15, 2005; 65(22): 10371 - 10380.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Banerjee, Y. Zhang, S. Ali, M. Bhuiyan, Z. Wang, P. J. Chiao, P. A. Philip, J. Abbruzzese, and F. H. Sarkar
Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic Cancer
Cancer Res., October 1, 2005; 65(19): 9064 - 9072.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Honeychurch, M. J. Glennie, and T. M. Illidge
Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody-Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells
Cancer Res., August 15, 2005; 65(16): 7493 - 7501.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. Steinaa, P. B. Rasmussen, A. M. Wegener, L. Sonderbye, D. R. Leach, J. Rygaard, S. Mouritsen, and A. M. Gautam
Linked Foreign T-Cell Help Activates Self-Reactive CTL and Inhibits Tumor Growth
J. Immunol., July 1, 2005; 175(1): 329 - 334.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Louvet, R. Labianca, P. Hammel, G. Lledo, M.G. Zampino, T. Andre, A. Zaniboni, M. Ducreux, E. Aitini, J. Taieb, et al.
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
J. Clin. Oncol., May 20, 2005; 23(15): 3509 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Camp, J. Summy, T. W. Bauer, W. Liu, G. E. Gallick, and L. M. Ellis
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
Clin. Cancer Res., January 1, 2005; 11(1): 397 - 405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. C. Rose and R. Wild
Therapeutic Synergy of Oral Taxane BMS-275183 and Cetuximab versus Human Tumor Xenografts
Clin. Cancer Res., November 1, 2004; 10(21): 7413 - 7417.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online